Arif Habib Announces Completion of Pfizer Pakistan Facility Acquisition

Karachi: Arif Habib has successfully completed the acquisition of a significant manufacturing facility from Pfizer Pakistan Limited, along with several high-value pharmaceutical products and trademarks, as confirmed on September 6, 2024.

According to information available from the Pakistan Stock Exchange (PSX), the transaction encompasses a strategic facility located at B2 SITE Karachi. The acquisition includes popular pharmaceutical products such as Ansaid, Ponstan, Ponstan Forte, Basoquin, Deltacortril, Lysovit, Corex-D, and Mycitracin. These products, known for their effectiveness in the medical community, are accompanied by their respective trademarks, secured through either an outright assignment or a perpetual license agreement.

The completion of this deal marks a pivotal step in Arif Habib’s expansion into the pharmaceutical sector, broadening its portfolio and enhancing its market presence. This move aligns with their strategic goals and is expected to contribute significantly to their growth trajectory in the healthcare industry.

The acquisition was executed following the guidelines outlined in Sections 96 and 131 of the Securities Act, 2015, along with compliance with the relevant provisions of the Rule Book of the Pakistan Stock Exchange Limited. TRE Certificate Holders have been informed of this major corporate development, which was finalized according to the terms set in the Asset Purchase Agreements between the involved parties.

The post Arif Habib Announces Completion of Pfizer Pakistan Facility Acquisition appeared first on .